VESTAKEEP® Polymers for Medical Applications

Evonik presents its new PEEK grades at MedTec

(PresseBox) ( Essen, )
For the first time, Evonik Industries, Essen, Germany, will present its VESTAKEEP® M series for medical applications at MedTec Europe in Stuttgart, March 3 to 5. The series is suitable for short-term body contact. It includes the medium-viscosity grade VESTAKEEP® M2G, the high-viscosity compound VESTAKEEP® M4G, and the powder grade VESTAKEEP® M4P.

The various biocompatibility tests according the United States Pharma-copoeia, in vivo and in vitro, are conducted by independent qualified laboratories. All test results have been negative.

In general, PEEK is used in medical products to improve their usefulness: lighter weight, more freedom of design, and better functional integration. It is also an inexpensive alternative to metals and other materials. Its performance is distinguished by the biocompatibility, the chemical resistance, the resistance against gamma rays or X-rays, and the X-ray transparency, the outstanding resistance to hot steam sterilization, the high mechanical strength and wear and impact resistances, good electrical insulation properties, and good hydrolysis resistance.

Even though VESTAKEEP® polymers have only recently been used in medical applications, the extensive property profile of the material predestines it for a number of interesting applications, like surgical instruments, endoscopes, applications in the in vitro-diagnostic, orthopedic, spinal, and dental fields, analytical equipment, and medical dosing.

Evonik has been successfully producing and marketing high-performance polymers for more than 40 years, and is highly valued in the market for its experience in application technology. The company has successfully applied its expertise in injection molding, extrusion, compression molding, and CAE (Computer-Aided Engineering) analysis to the VESTAKEEP® compounds, which were introduced into the product portfolio in 2007 and made available to Evonik's newly acquired development partners. The collaboration is designed on the basis of a long-term partnership, which also allows for fairly long accreditation periods.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an